Takeda Pharmaceutical Co. Ltd. · TSE:4502
Takeda Pharmaceutical — Investor Day (November 2019)
34 slides from Takeda Pharmaceutical's investor day presentation, Nov 15, 2019
Slide 1: Realizing the Potential of Plasma-Derived Therapies
Realizing the Potential of Plasma‐Derived Therapies Investor Relations Day, Covington, GA 15th November 2019 Julie Kim President, Plasma‐Derived Therapies Business Unit (PDT BU) IMPORTANT NOTICE For the purposes of this notice, “presentation” means this document, any oral presentation, any question
Slide 2: Agenda
Thank you to the Georgia BioScience Training Center Front Entrance Room 139 Room 125 Room 124 Back Entrance 2 Agenda PDT Overview Julie Kim, President, PDT BU Lunch buffet PDT R&D Overview Christopher Morabito, Head, R&D, PDT Covington Site Introduction Carlos Soto, Covington Site Head Q&A Sue Brown
Slide 3: Introducing Takeda's Plasma-Derived Therapies Business
Introducing Takeda’s Plasma‐Derived Therapies Business Julie Kim President, Plasma‐Derived Therapies Business Unit Plasma‐derived therapies are critical, life‐saving medicines, relied upon by thousands of people worldwide with rare and complex diseases Lynayah’s Family I probably wouldn’t have lived
Slide 4: Plasma presents a unique opportunity
Plasma presents a unique opportunity 1 2 3 4 5 Plasma is a durable Products have Indication Not subject to Probability of Market business with lifecycle expansion patent cliffs success for demand compelling growth spanning continues R&D is continues to opportunity… decades generally high grow steadi
Slide 5: Plasma still has significant untapped therapeutic potential
And plasma still has significant untapped therapeutic potential Multiple factors influence plasma protein By advancing our understanding metabolism and effects in individuals of plasma proteins, we can: • Predict how different patients metabolize plasma proteins, and drive Health individualization o
Slide 6: Building on a long history of bringing innovative therapies to patients
We are building on a long and successful history of bringing innovative therapies to patients Hyland 1941 1952 1960 1968 1994 1996 2005 2006 2010 2013 2015 2016 2019 Albumin First commercial Albumin Only FVIII facilitated IG with up to 1/month infusions PLASMA‐VAC First commercial FVIII concentrate
Slide 7: Our PDT BU leadership team and ambition
Our PDT BU leadership team draws on, and brings together, Takeda’s extensive plasma experience and broader expertise across our business Julie Kim Ingrid Hofström Emi Psachoulia Sue Brown Christopher Michael Shires Shady Annick Ramy Riad Luana Banu Deborah Hibbett Head of Plasma‐ Executive Chief of
Slide 8: Our strategy and targeted investments extend across the entire value chain
Our strategy and targeted investments extend across the entire value chain PLASMA SOURCING MANUFACTURING COMMERCIALIZATION RESEARCH & DEVELOPMENT 14 PLASMA SOURCING MANUFACTURING COMMERCIALIZATION RESEARCH & DEVELOPMENT 15
Slide 9: BioLife is an industry leader in sourcing high-quality plasma
BioLife, part of Takeda’s Plasma‐Derived Therapies Business Unit, is an industry leader in the sourcing of high‐quality plasma Broad global footprint Recognized expertise 140+ collection centers across Trained medical staff at each center four countries Dedicated quality, regulatory and Plasma sourc
Slide 10: Accelerating plasma collection through third parties and acquisition
We are accelerating the rate of plasma collection and incrementally increasing overall volume through third parties and acquisition We are building momentum…. Increased plasma volumes by approximately 20% in 2018 Expanded European presence from 7 to 30 collection centers within past 12 months Comple
Slide 11: World-leading plasma-derived therapies manufacturing network
PLASMA SOURCING MANUFACTURING COMMERCIALIZATION RESEARCH & DEVELOPMENT 20 We have a world‐leading plasma‐derived therapies manufacturing network in which we continue to significantly invest Covington, GA 8 STRATEGIC LOCATIONS Sanquin, NL Vienna, Austria plus four strategic partners, allowing Round L
Slide 12: Global network leveraging operational excellence across sites
The global network builds on the strengths of each location while leveraging operational excellence across the sites Mass Capture, Fractionation Los Angeles, USA Rieti, Italy Vienna, Austria Sanquin, NL Covington, USA Downstream Processing Lessines, Belgium Covington, USA Round Lake, USA Pisa, Italy
Slide 13: World-class safety capabilities in plasma donation and pathogen safety
Takeda has world‐class safety capabilities and an unsurpassed reputation in both plasma donation and pathogen safety Donation safety standards Strict donation Donation Strong Plasma screening, criteria and frequency inspection inventory hold and look screening at management record back procedure eac
Slide 14: Broad and differentiated portfolio of plasma-derived therapies
Our broad and differentiated portfolio of plasma‐derived therapies treats rare and complex diseases worldwide ATIII 26 For illustrative purposes only, geographies and products do not correspond Our two SCIG brands complement each other and address different patient needs • Similar efficacy to IVIG a
Slide 15: Global supply is not keeping up with demand for IG therapies
Currently, global supply is not keeping up with demand for IG therapies STRONG & CONTINUED IG DEMAND The Global Polyvalent IG Market (IVIG/SCIG) IG is increasingly recognized for its diverse from 2000 to 2016, with Projected Global Demand Through 2024 therapeutic value, and is expected to grow in Mi
Slide 16: Personalized, lifelong care and growth opportunities across portfolio
Our goal is to continue to bring personalized, innovative, lifelong care to as many people as possible throughout the patient journey Diagnosis Access Partnership with large hospital Sustainable pricing systems in the US to leverage Dedicated access support electronic medical records Patient assista
Slide 17: Trajectory to improve PDT business performance
And we are embarking on a trajectory to improve overall Plasma‐ Derived Therapies business performance Key Growth & Margin Drivers for PDT Key Financial Aspiration for PDT* • Focused sustainable, value‐based commercial Annual revenues strategies, including tenders (CAGR) Mid to high single digit • P
Slide 18: A New Dedicated Focus on Innovative, Sustainable Solutions for PDT
A New Dedicated Focus on Innovative, Sustainable Solutions for Plasma‐Derived Therapies Christopher Morabito, M.D. Head of R&D, Plasma‐Derived Therapies PDT R&D’s credentials and infrastructure are well‐established Partobulin Albumin (Austria, Health Ministry Approval) 1941 1952 1968 1968 1986 1994
Slide 19: Independence brings focus on plasma with access to broader R&D
Our independence brings focus on plasma and is bolstered by access to broader R&D capabilities and resources Focused entirely on plasma‐derived therapies Lean and agile team PDT Based in Cambridge, MA and Vienna, Austria R&D Separate R&D prioritization Dedicated budget Global R&D Common Takeda value
Slide 20: PDT R&D Strategy
We are driving a culture of innovation through two R&D engines Research/Early Development Late Development Translational Integrated Pharmaceutical Care Solutions Sciences Translational Research Pharm Sci and Devices Early Development Innovation Engine Late Development Innovation Engine Generate new
Slide 21: Prioritizing near-term late development
We are prioritizing near‐term late development… RESEARCH / NON‐CLINICAL DEVELOPMENT LATE DEVELOPMENT CUVITRU HYQVIA HYQVIA Halozyme Halozyme Wearable Device US ‐ Pediatric PID EU ‐ Pediatric PID HYQVIA HYQVIA ‐ HyHub Halozyme IMMUNOLOGY Flextronics Chronic inflammatory demyelinating Delivery Device
Slide 22: Allocating resources to research and early development
Over the next 3 years, we plan to allocate resources to research and early development Estimated % of PDT R&D spend for FY2023 Distribution of PDT R&D spend for FY2019 60% ~70% of resources will be allocated to improving in‐line products and production efficiencies 95% 10% Optimizing value of in‐lin
Slide 23: Immunoglobulins provide the scaffold for PDT innovation
Immunoglobulins provide the scaffold for PDT innovation Current State US & EU IgG use by indication* Exploring efficacy and safety of HYQVIA in patients with PID and other immunology neuro‐immune diseases (e.g. CIDP) Ongoing delivery device development SID Other SID 4% PID 15% Opportunities 26% Indi
Slide 24: PROTHROMPLEX TOTAL and ARALAST & GLASSIA opportunities
PROTHROMPLEX TOTAL can be developed to treat a variety of bleeding disorders Changing Treatment Paradigm (EU Total Prescriptions) 37% 31% 45% Current State 70% 62% 53% Many different mechanisms used for prophylactic and surgical anti‐ coagulant therapy 55% 63% 69% 38% 47% PROTHROMPLEX TOTAL use is l
Slide 25: Investigational A1AT-replacement formulations
Investigational A1AT‐replacement formulations may offer additional value to patients* Short term Mid term In Vivo Model Highly purified post‐ Protein Modification PK parameters for a modified A1AT fractionations site‐specific modification leading to have been assessed in vivo pdA1AT‐precursor an ext
Slide 26: Improving manufacturing efficiencies to increase yield
We are further improving manufacturing efficiencies to increase yield High yield high throughput initiatives will improve delivery of last liter products to patients globally A new high yield & high throughput process: Process development to shorten IgG upstream and total albumin cycle times Capture
Slide 27: Untapped potential in plasma proteins and near-term growth
We believe there is a tremendous amount of untapped potential in plasma proteins Homeostasis >3000 plasma proteins control balance, some with health promoting effects and other with disease associated effects Disease Generally, PDTs have been developed to replace functional deficiencies in health pr
Slide 28: Treatment paradigms are dynamic and we are innovating continuously
Treatment paradigms of rare and complex diseases are dynamic and we are innovating continuously Uncertainties PDT Innovation Deepening understanding of underlying Directed most appropriate uses of PDTs mechanisms of diseases and co‐morbidities With Takeda Global R&D, investigate plasma‐drug combinat
Slide 29: Introducing our Covington Manufacturing Facility
Introducing our Covington Manufacturing Facility Carlos Soto Covington Site Head 56 This was our starting place in October 2012 57
Slide 30: Vision and plans for Covington
Our vision and plans for Covington enable us to serve more patients as we continue to ramp up our operations Increases capacity for Investment of Manufacturing Takeda will employ $1 BILLION+ campus covers ~1,500 EMPLOYEES PLASMA‐DERIVED THERAPIES 1 MILLION+ FT2 in Georgia at full ramp up 2012 2014 2
Slide 31: Our current footprint allows for further expansion
Our current footprint allows for further expansion Today, we manufacture these therapies from plasma proteins GAMMAGARD Liquid FLEXBUMIN 61
Slide 32: Our facility is vertically integrated
Our facility is vertically integrated Fully integrated end-to-end production site • ~1000 employees today Plasma testing Fractionation Purification Filling Packaging / ramp up plan in place • Site includes already approved BioLife testing and storage facility Flexible design for future expansion Fra
Slide 33: Creating impact together
Creating impact together Through a dedicated plasma business unit, we will reimagine the plasma industry and uncover the full potential of plasma‐ derived therapies to benefit patients worldwide 64 65
Slide 34: Presenters
Sue Brown Julie Kim Christopher Adrian Murphy Costa Saroukos Carlos Soto Head, Global President, PDT BU Morabito Head of Plasma Chief Financial Officer Covington Site Head BioLife Operations Head R&D, PDT Operating Unit, Global Manufacturing & Supply 66
Takeda Pharmaceutical Company — Investor Day (November 2019) on 6ix